Levo-Methasan

Levomethadone Hydrochloride, the active ingredient in Levo-Methasan, is an opioid analgesic presented as an oral tablet for oral use. It is employed in the management of opioid dependence and chronic pain in adult patients, helping to reduce withdrawal symptoms and provide analgesia.

GNH USA supplies Levo-Methasan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levo-Methasan, an opioid analgesic, is used in conditions related to opioid dependence and pain management.

- Opioid dependence: helps stabilize patients by reducing withdrawal symptoms and cravings. - Chronic pain: provides analgesia for severe, persistent pain when other treatments are insufficient. - Opioid withdrawal: alleviates acute withdrawal signs during detoxification.

Levo-Methasan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset. - Constipation: reduced bowel movements. - Drowsiness: increased sleepiness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - QT interval prolongation: cardiac rhythm disturbance. - Severe hypotension: marked drop in blood pressure.

Before prescribing Levo-Methasan, clinicians should consider several safety measures. - Assess patient history: evaluate for respiratory disorders, cardiac disease, and liver impairment. - Monitor for sedation: observe for excessive drowsiness or impaired cognition. - Avoid abrupt discontinuation: taper dose to prevent withdrawal. - Use caution with CNS depressants: limit concurrent use of alcohol, benzodiazepines, or other opioids. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and light.

Levo-Methasan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concomitant opioids: risk of additive respiratory depression. - CNS depressants (benzodiazepines, barbiturates, alcohol): may cause profound sedation. - CYP3A4 inhibitors (ketoconazole, erythromycin): increase levomethadone plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine): may reduce efficacy. - QT‑prolonging agents (certain antiarrhythmics, antipsychotics): increase cardiac risk. - Serotonergic drugs (SSRIs, MAO inhibitors): potential for serotonin syndrome.